Physician profile
Elizabeth Froman
NPI 1821031295
$169,683.11
in general payments reported to CMS, 2019-2025
22 companies · $31K in 2025
The $31K reported for 2025 was more than what 99% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69.30 · 2020: $20K · 2021: $30K · 2022: $27K · 2023: $30K · 2024: $31K · 2025: $31K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $92K · Food and Beverage: $637.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $92,400.00 |
| Food and Beverage | $637.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Plasma INC. | $92,400.00 | 2023-2025 | |
| Csl Behring | $76,450.00 | 2020-2022 | |
| Ironshore Pharmaceuticals INC. | $188.95 | 2019-2024 | |
| Corium, LLC | $115.65 | 2023-2025 | Azstarys |
| Collegium Pharmaceutical, INC. | $77.16 | 2025 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $64.46 | 2025 | Rexulti |
| Sanofi Pasteur INC. | $46.58 | 2022-2024 | |
| Eisai INC. | $43.62 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $36.35 | 2021-2023 | Flumist Quadrivalent |
| Kowa Pharmaceuticals America, INC. | $33.06 | 2025 | Zoryve |
| Takeda Pharmaceuticals U.S.A., INC. | $31.53 | 2022-2023 | Gattex |
| The Binding Site INC. | $23.30 | 2025 | Freelite |
| Merck Sharp & Dohme LLC | $22.77 | 2023 | Belsomra |
| Supernus Pharmaceuticals, INC. | $21.78 | 2022 | |
| Biogen, INC. | $18.13 | 2024 | Skyclarys |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.51 | 2025 | Caplyta |
| Phadia US INC. | $17.01 | 2019 | |
| Sun Pharmaceutical Industries INC. | $16.83 | 2021 | |
| Lundbeck LLC | $16.36 | 2025 | Rexulti |
| Biocompatibles, INC. | $14.94 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.82 | 2025 | Spravato |
| Abbott Laboratories | $13.30 | 2023 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Froman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.